Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

CERAD was funded by the National Institute on Aging with a mandate to standardize assessment in Alzheimer's disease. Accordingly, this program developed and evaluated clinical, neuropsychological and neuropathological assessments, an approach to neuroimaging, a standardized means of obtaining family history, and a behavior rating scale, as well as other measures. Training tapes are available for relevant assessments. Many of these measures have been translated into a number of languages, and used for both clinical evaluation and in epidemiological studies. Longitudinal information on over 1,000 patients with Alzheimer's disease and nearly 500 controls from 24 major medical centers across the U.S. has been written to CD, and is available for analysis. CERAD materials and a bibliography are available from the CERAD main office.

Key findings

Why it matters

CERAD developed and evaluated standardized clinical, neuropsychological, and neuropathological assessments for Alzheimer's disease. These measures have been translated into multiple languages and used in clinical and epidemiological studies.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 40 of the 68 points it could be judged on, which is 59 of 100. Total 59 of 100.40 of the 68 points we could judge = 59 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here and still being cited, so those were left out: it earned 40 of the 68 points we could judge it on, which is 59 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Principles and Practice of Geriatric Psychiatry)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2002 — older than 20 years, still counted
Sample size 3 / 4 1,000 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 Citation count not trusted: 18 of 172 library studies citing it were published more than a year before it - a sign OpenAlex merged several works under this DOI — left out of this score
Citations per year — / 5 Citation count not trusted (see above) — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Library citations not trusted (see above) — left out of this score
Still being cited — / 4 Citation count not trusted (see above) — left out of this score
Senior author's track record 2 / 4 Last-listed author Albert Heyman: h-index 46 (OpenAlex, whole career)
Institution's track record 2 / 3 Duke University: institution h-index 1,541 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 40 / 68 Scored on 14 of 20 parts. We have no data for the rest, so they are left out: 40 of the 68 points we could judge it on is 59 out of 100.
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Fillenbaum, G. G., & Heyman, A. (2002). Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Principles and Practice of Geriatric Psychiatry. https://doi.org/10.1002/0470846410.ch42(iii)

Vancouver

Fillenbaum GG, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Principles and Practice of Geriatric Psychiatry. 2002. doi:10.1002/0470846410.ch42(iii).

BibTeX

@article{fillenbaum2002-ac049f00,
  author  = {Fillenbaum, Gerda G. and Heyman, Albert},
  title   = {{Consortium to Establish a Registry for Alzheimer's Disease (CERAD)}},
  journal = {Principles and Practice of Geriatric Psychiatry},
  year    = {2002},
  doi     = {10.1002/0470846410.ch42(iii)},
  url     = {https://doi.org/10.1002/0470846410.ch42(iii)}
}

Later studies that cite this one

172 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Cognitive tests and assessment

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →